BamSEC and AlphaSense Join Forces
Learn More

Aerie Pharmaceuticals Inc

Formerly NASDAQ: AERI
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.1
from 8-K 5 pages Aerie Pharmaceuticals, Inc. and Wilmington Trust, National Association, as Trustee First Supplemental Indenture Dated as of November 21, 2022 to the Indenture Dated as of September 9, 2019 1.50% Convertible Senior Notes Due 2024
12/34/56
EX-4.4
from S-8 1 page Second Amendment of the Aerie Pharmaceuticals, Inc. Second Amended & Restated Inducement Award Plan
12/34/56
EX-4.3
from 10-K 4 pages Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.3
from 10-K 4 pages Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.3
from 10-K ~5 pages Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.1
from 8-K 103 pages Aerie Pharmaceuticals, Inc. and Wilmington Trust, National Association as Trustee Indenture Dated as of September 9, 2019 1.50% Convertible Senior Notes Due 2024
12/34/56
EX-4.2
from 8-K 19 pages Registration Rights Agreement
12/34/56
EX-4.1
from 8-K 15 pages Exchange and Termination Agreement
12/34/56
EX-4.2
from S-8 25 pages Aerie Pharmaceuticals, Inc. Second Amended & Restated Inducement Award Plan
12/34/56
EX-4.2
from S-8 25 pages Aerie Pharmaceuticals, Inc. Amended & Restated Inducement Award Plan
12/34/56
EX-4.2
from S-8 25 pages Aerie Pharmaceuticals, Inc. Inducement Award Plan
12/34/56
EX-4.1.1
from 10-K 17 pages First Amendment to Note Purchase Agreement
12/34/56
EX-4
from SC 13D/A 1 page This Letter Confirms That Clive Bode and David Reintjes Are Authorized and Designated to Sign All Securities Related Filings With the Securities and Exchange Commission, Including Form Id Acknowledgements, on My Behalf. This Authorization and Designation Shall Be Valid for Three Years From the Date of This Letter and Supersedes the Authorization and Designation Letter Dated July 1, 2013. Very Truly Yours, /S/ David Bonderman David Bonderman
12/34/56
EX-4.3
from 10-Q 32 pages Security Agreement Among Aerie Pharmaceuticals, Inc. and Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P. and Deerfield Special Situations International Master Fund, L.P. as Purchasers and Deerfield Management Company, L.P. as Agent for the Purchasers September 8, 2014 Security Agreement
12/34/56
EX-4.1
from 10-Q 62 pages Article 1 Definitions
12/34/56
EX-4.1
from S-1/A 2 pages Indenture or similar
12/34/56